ZUPLENZ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZUPLENZ (ZUPLENZ).
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
| Metabolism | Hepatic, primarily via CYP3A4, CYP1A2, and CYP2D6; first-pass metabolism. |
| Excretion | Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized |
| Half-life | Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours |
| Protein binding | 60% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 2.4 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 65% (due to first-pass metabolism); IV: 100% |
| Onset of Action | Oral: 30-60 minutes; IV: within 5 minutes |
| Duration of Action | 8-12 hours; prolonged in renal impairment |
| Molecular Weight | 293.4 |
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
| Dosage form | FILM |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, reduce dose to 4 mg intraorally once daily. |
| Liver impairment | Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Maximum daily dose of 8 mg intraorally, administered as a single dose. |
| Pediatric use | Children aged 6 months to 12 years: 0.15 mg/kg/dose (maximum 8 mg per dose) intraorally 30 minutes before chemotherapy; may repeat once after 4 hours if vomiting persists. |
| Geriatric use | No specific dose adjustment recommended; however, elderly patients may have reduced renal function, so consider monitoring renal function and adjust dose if GFR <30 mL/min. |
| 1st trimester | Zuplenz (ondansetron) use in first trimester is not recommended due to limited safety data; however, no consistent evidence of major teratogenicity exists. |
| 2nd trimester | Use in second trimester is considered relatively safe; monitor for maternal QT prolongation and electrolyte imbalances. |
| 3rd trimester | Avoid use near term due to risk of QT prolongation in neonate and potential for maternal cardiac arrhythmias. |
Clinical note
Comprehensive clinical and safety monograph for ZUPLENZ (ZUPLENZ).
| Placental transfer | Ondansetron crosses the placenta with a placental transfer ratio of approximately 0.4-0.5; detectable in fetal serum at levels comparable to maternal serum. |
| Breastfeeding | Ondansetron is excreted into breast milk in low amounts (estimated relative infant dose <5%). No adverse effects reported in infants; however, caution is advised due to potential for QT prolongation. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to ondansetronConcurrent use of apomorphine
| Precautions | Serotonin syndrome (especially when used with other serotonergic drugs); QT prolongation (avoid in patients with pre-existing QT prolongation or electrolyte abnormalities); acute dystonic reactions; masked paralytic ileus. |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect ondansetron metabolism. Avoid alcohol as it may worsen nausea and side effects. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Data from human pregnancies are inadequate; animal studies have not shown teratogenic effects. Second and third trimesters: No evidence of fetal harm. Zuplenz (ondansetron) is classified as FDA Pregnancy Category B; however, recent studies suggest a small increased risk of oral clefts when used in the first trimester. Overall risk is considered low. |
| Fetal Monitoring | No specific maternal-fetal monitoring required beyond standard prenatal care. Monitor for maternal adverse effects such as QT prolongation, serotonin syndrome, or hypersensitivity. |
| Fertility Effects | No known effects on fertility based on animal studies; human data are insufficient. |
| Zuplenz (ondansetron oral soluble film) is a 5-HT3 receptor antagonist for prevention of nausea and vomiting. The film dissolves on the tongue without water, beneficial for patients with difficulty swallowing or active emesis. Administer at least 30 minutes before chemotherapy or radiotherapy. Peak effect correlates with the Tmax of ondansetron (~2 hours). Avoid use in patients with congenital long QT syndrome; monitor electrolytes and ECG in those with cardiac risk factors. May mask progressive ileus or gastric distension. |
| Patient Advice | Place the film on your tongue; it will dissolve in seconds. Do not chew or swallow it whole. · Take this medication exactly as prescribed, usually 30 minutes before chemotherapy or radiation. · Do not eat or drink anything for at least 5 minutes after the film dissolves to allow full absorption. · Common side effects include headache, constipation, or feeling tired. Report chest pain, fast or irregular heartbeat, or severe dizziness. · Avoid driving if you feel dizzy or drowsy until you know how this drug affects you. |